Beirne Wealth Consulting Services LLC Has $779,000 Holdings in Eli Lilly and Company $LLY

Beirne Wealth Consulting Services LLC grew its holdings in Eli Lilly and Company (NYSE:LLY) by 246.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,020 shares of the company’s stock after buying an additional 726 shares during the period. Beirne Wealth Consulting Services LLC’s holdings in Eli Lilly and Company were worth $779,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Key Client Fiduciary Advisors LLC raised its position in shares of Eli Lilly and Company by 1.2% in the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock valued at $867,000 after purchasing an additional 13 shares during the period. Darwin Wealth Management LLC boosted its holdings in shares of Eli Lilly and Company by 3.6% during the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock worth $285,000 after buying an additional 13 shares during the period. Christensen King & Associates Investment Services Inc. grew its stake in Eli Lilly and Company by 1.2% in the 3rd quarter. Christensen King & Associates Investment Services Inc. now owns 1,139 shares of the company’s stock valued at $869,000 after buying an additional 13 shares during the last quarter. Barnes Dennig Private Wealth Management LLC raised its holdings in Eli Lilly and Company by 2.1% in the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 628 shares of the company’s stock valued at $479,000 after acquiring an additional 13 shares during the period. Finally, Atwater Malick LLC raised its holdings in Eli Lilly and Company by 1.3% in the 3rd quarter. Atwater Malick LLC now owns 1,018 shares of the company’s stock valued at $777,000 after acquiring an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced a roughly $1 billion AI investment aimed at accelerating drug discovery and strengthening its pipeline beyond GLP‑1 drugs; analysts and retail investors view this as a structural growth lever that supports longer‑term revenue diversification and investor enthusiasm following the Q4 beat. Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery
• Positive Sentiment: Topline results from the Phase 3 LIBRETTO‑432 trial show Retevmo (selpercatinib) delivered a highly statistically significant and clinically meaningful improvement in event‑free survival as adjuvant therapy in early‑stage RET fusion‑positive NSCLC — a clear clinical win that expands Lilly’s oncology franchise and increases future revenue/pipeline value. Lilly’s Retevmo (selpercatinib) delivers substantial event-free survival benefit
• Positive Sentiment: Lilly has built about $1.5 billion of inventory of a weight‑loss pill ahead of a planned global launch this summer, signaling commercial readiness and management’s expectation of strong demand that could accelerate near‑term revenue growth. Eli Lilly (LLY) Builds $1.5 Billion Inventory of Weight-Loss Pill
• Positive Sentiment: Coverage highlights Lilly’s strategic moves beyond GLP‑1s — including RNA cancer programs, AI‑enabled discovery and obesity R&D — which reduce single‑product risk and support a multi‑pillar growth narrative. Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets
• Neutral Sentiment: Lilly will participate in TD Cowen’s Health Care Conference on March 2 (CFO Lucas Montarce to speak); investors will watch for management commentary and any updated guidance or details on commercialization plans. Lilly to participate in TD Cowen’s 46th Annual Health Care Conference

Analysts Set New Price Targets

LLY has been the topic of several research reports. TD Cowen upped their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. The Goldman Sachs Group set a $1,260.00 price target on Eli Lilly and Company in a research note on Thursday, February 5th. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,290.00 to $1,313.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Guggenheim dropped their target price on Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Finally, Loop Capital set a $1,200.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,218.88.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,040.12 on Tuesday. The company has a market cap of $981.21 billion, a price-to-earnings ratio of 45.32, a PEG ratio of 1.21 and a beta of 0.39. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. The stock has a fifty day moving average price of $1,053.28 and a 200-day moving average price of $910.46.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the previous year, the firm earned $5.32 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is currently 30.15%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.